收费全文 | 520篇 |
免费 | 112篇 |
国内免费 | 19篇 |
儿科学 | 3篇 |
基础医学 | 12篇 |
口腔科学 | 2篇 |
临床医学 | 89篇 |
内科学 | 30篇 |
皮肤病学 | 4篇 |
神经病学 | 12篇 |
外科学 | 4篇 |
综合类 | 19篇 |
预防医学 | 18篇 |
眼科学 | 3篇 |
药学 | 423篇 |
中国医学 | 24篇 |
肿瘤学 | 8篇 |
2024年 | 2篇 |
2023年 | 24篇 |
2022年 | 17篇 |
2021年 | 27篇 |
2020年 | 47篇 |
2019年 | 48篇 |
2018年 | 27篇 |
2017年 | 40篇 |
2016年 | 31篇 |
2015年 | 48篇 |
2014年 | 43篇 |
2013年 | 62篇 |
2012年 | 31篇 |
2011年 | 33篇 |
2010年 | 23篇 |
2009年 | 29篇 |
2008年 | 15篇 |
2007年 | 19篇 |
2006年 | 16篇 |
2005年 | 6篇 |
2004年 | 11篇 |
2003年 | 9篇 |
2002年 | 10篇 |
2001年 | 8篇 |
2000年 | 8篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 4篇 |
1993年 | 1篇 |
1992年 | 1篇 |
Areas covered: This narrative review examines the current state of pharmacovigilance for biologics in the European Union (EU) and discusses relevant information on pharmacovigilance of biosimilars, the current EU pharmacovigilance system, and areas that could be improved.
Expert opinion: Although steps have been taken to improve pharmacovigilance of biologics in the EU, several enhancements can still be made, including additional training for healthcare professionals on ADR reporting, the use of 2D barcodes that enhance traceability, and an open discussion of potentially missed opportunities in the pharmacovigilance of biosimilars. 相似文献
Research design and methods: A sample of 1139 reports received by the Shaanxi ADR Monitoring Center from January 2015 to December 2017 was selected. ADR report quality was evaluated using an ADR report quality evaluation system.
Results: None of the reports were rated as excellent and 1.40% (n = 16) as good. Report quality was better for new and serious reports than for general reports. Medical institutions generated higher quality reports than pharmaceutical manufacturers. Nurses generated higher quality reports than doctors, pharmacists, and other professionals. Reporters of different occupations showed significant differences in the quality of the indicators Reporting time limit, Intervention ADR time, ADR termination time, ADR intervention measures, Original disease, and Cause of medication (P = 0.000).
Conclusions: The ADR data quality was poor in western China, and of lower quality than reported data from previous research in other regions. Improvements in the quality and availability of ADR reports are urgently needed. 相似文献